South Korea's Ubix Therapeutics, Inc., a pioneer in Targeted Protein Degradation (TPD) technology, has successfully raised $19.5M in a Pre-IPO round led by both new and existing investors, including Solidus Investment, Atinum Investment, and QUAD Investment Management. The funding aims to fuel clinical trials, expand their drug pipeline, and accelerate IPO preparations, showcasing significant global potential in refractory cancer treatments. WOW Partners(와우파트너스) https://lnkd.in/em3uTrNd #lifesciences
